Strategies for optimal suppression of rheumatoid arthritis
Kooij, S.M. van der
Citation
Kooij, S. M. van der. (2009, January 22). Strategies for optimal suppression of rheumatoid arthritis. Retrieved from https://hdl.handle.net/1887/13425
Version: Corrected Publisher’s Version
License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the
University of Leiden
Downloaded from: https://hdl.handle.net/1887/13425
Note: To cite this publication please use the final published version (if
applicable).
Strategies for optimal suppression of
rheumatoid arthritis
Strategies for optimal suppression of Rheumatoid Arthritis
Proefschrift
ter verkrijging van de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus
prof. mr. P.F. van der Heijden, volgens besluit van het College voor Promoties
te verdedigen op donderdag 22 januari 2009
klokke 16.15 uur door
Sjoerd Martijn van der Kooij geboren te Leiderdorp
in 1976
promotores Prof. Dr. T.W.J. Huizinga Prof. Dr. B.A.C. Dijkmans VU Medisch Centrum, Amsterdam
copromotores Dr. C.F. Allaart Dr. P.J.S.M. Kerstens
Jan van Breemen Instituut, Amsterdam
referent Dr. R.F. van Vollenhoven Karolinska Institutet, Stockholm
overige leden Prof. Dr. F.C. Breedveld
Prof. Dr. D.M.F.M. van der Heijde
The research presented in this thesis was performed at the Rheumatology Department of Leiden University Medical Centre, Leiden, The Netherlands. The research was financially supported by the Dutch College of Health Insurances, with additional funding by Schering-Plough B.V. and Centocor Inc.
© Sjoerd van der Kooij, 2008.
No Part of this thesis may be reproduced in any form without written permission from the author or, when appropriate, of the publishers of the publications.
isbn 978-90-9023844-9
Foto omslag Frans Jansen, Hollandse Hoogte Vormgeving Sam Gobin, Leiden
Druk Drukkerij Mostert & Van Onderen, Leiden
Financial support for the publication of this thesis was provided by ABBOTT B.V., Amgen B.V., Artrose & Reuma Stichting, AstraZeneca B.V., Bristol-Myers Squibb B.V., Centocor B.V., J.E. Jurriaanse Stichting, MSD B.V., Pfizer B. V., het Reumafonds, Roche Nederland B.V., Schering-Plough B.V. en Teva Pharma NL.
Inhoud
1 General introduction –General introduction – 7
2 Innovative treatment strategies for patients with rheumatoidInnovative treatment strategies for patients with rheumatoid arthritis – 21
3 Probability of continued low disease activity in patients withProbability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score – 33
4 Limited efficacy of conventional DMARDs after initial metho-Limited efficacy of conventional DMARDs after initial metho- trexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score – 41
5 A clinical pharmacogenetic model to predict the efficacy of metho-A clinical pharmacogenetic model to predict the efficacy of metho- trexate monotherapy in recent-onset rheumatoid arthritis – 55
6 Patient-reported outcomes in a randomized trial comparingPatient-reported outcomes in a randomized trial comparing four different treatment strategies in recent onset rheumatoid arthritis – 71
7 Drug-free remission, functioning and radiographic damage after 4Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis – 85
8 Clinical and radiological efficacy of initial versus delayedClinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis – 99
9 General discussion and conclusion – 11General discussion and conclusion – 111 Nederlandse Samenvatting – 11Nederlandse Samenvatting – 119 Role of the funding source – 12Role of the funding source – 125 Acknowledgements – 12Acknowledgements – 125 List of publications – 12List of publications – 126 Curriculum vitae – 12Curriculum vitae – 127 DankwoordDankwoord – 128
